Corticosteroid preparations have been found to be of immense value in a great many conditions in ophthalmology. Here I am concerned with adverse reactions of such therapy on the eye. When steroids are given to a patient numerous metabolic processes are altered of which only a small proportion are beneficial. The interest in this subject is much more than simple prevention of complications. If one can work out the mechanisms of adverse reactions, preferably at a cellular or molecular level, this will not only help in designing new therapeutic agents but also provide information on certain basic processes of ocular disease.
Ocular adverse reactions to corticosteroid therapy may arise from systemic or local administration. These reactions may be classified in terms of the three main groups of mechanisms and a fourth miscellaneous group: (1) Side-effects or exaggerated physiological action collectively termed hypercortism. (2) Adrenocortical insufficiency. (3) Secondary effects or the indirect consequence of therapy. (4) Unclassified where the mechanism is in doubt or unknown.
Side-effects
Swelling of the lids occurs as part of the moon face and is usually described as abnormal fat deposition though there seems doubt on the nature of the swelling. Chemosis is used as a sensitive index of steroid overdosage by some physicians. Acute myopia seems to be very rare (Grant 1962) but minor refractive changes are encountered more commonly.
A central form ofmyopathy has been described, especially following triamcinolone or dexamethasone, but the involvement of ocular muscles has not, so far as I am aware, been established. I have observed ptosis and limitation of ocular movements in some patients. Electromyography should 'help to differentiate myopathy from general muscle weakness.
Hypertensive retinopathy can occur on steroid therapy and is usually of a mild degree. Diabetic retinopathy is a complication which has only been reported in experimental animals. Thus, in the Chinese hamster, administration of cortisone and growth hormone to a breed with the appropriate trait leads to a retinopathy with some features similar to that in man (Hausler et al. 1963) . Becker (1952) found that alloxan-induced diabetes was complicated by retinal microaneurysms only if corticotrophin was also given to the animals, but this work has not been confirmed.
It has been suggested that children whose growth is stunted by steroid therapy may have abnormally transparent or blue sclerotics. Patients with scleritis are often found to be refractory to corticosteroids and some of these develop an alarming transparency, with thinning and ectasia of the sclera (Grant 1962) . The area affected -may remain localized or involve the whole circumference of the anterior sclera. This can result from the disease process alone though it may be accentuated by the steroid therapy. Overlay grafts are sometimes performed with sclera, fascia or aorta. However, histology in one such patient who developed scleritis whilst on steroids showed that the sclera was in fact thickened in the transparent area; abnormal mucopolysaccharides may account for the translucency.
Subconjunctival hemorrhages may be seen in patients exhibiting also purpura and bruising. I have only observed retinal hemorrhages in one such patient.
Adrenocortical Insufficiency
The sudden collapse at times of stress of patients on therapy is something for which we should all be prepared. Now that the majority of patients carry personal cards indicating details of treatment, supplementary therapy can be readily employed. This insufficiency can, however, last for a period up to a year after cessation of steroids.
There is one condition with ocular signs thought to be related to adrenocortical insufficiency and that is the rare, but serious, intracranial hypertension. Approximately 28 children or young adults, the oldest of whom is 19, have been reported. The literature is summarized in the Lancet (1964) .
Therapy has usually been given for about two and a half years and then decreased or changed to another preparation. The onset can be quite dramatic with headaches, vomiting, drowsiness or coma. Ocular palsies, chiefly VI nerve, have been reported. All cases have papilleedema in some of which enlargement of the blind spot can be demonstrated. Lumbar puncture reveals a high pressure but the fluid is otherwise normal. Small ventricles are found and cerebral cedema has been observed before and after death.
The treatment is to give supplementary steroids or decompress if necessary, then to withdraw steroids gradually. There is an identical condition described in Addison's disease (Walsh 1952 , Jefferson 1956 . In both groups it should be stressed that children have died because the condition was not recognized. It would be interesting to know whether the adrenal function was normal in the steroid group before therapy was commenced; an estimation before prolonged medication is contemplated in children might prevent this disaster.
Two fatalities have occurred in asthmatic children fairly recently in Birmingham; they were on quite low dosage of steroids and showed the main features of this condition. In each an attack of status asthmaticus appeared to precipitate the adrenal insufficiency and though papillcedema and raised CSF pressure were detected the urgency of the situation was not obvious.
Although it is not reported in the literature papillcedema has been ascribed to steroid therapy in adults (Walsh, personal communication) . This condition is practically symptom free, the papillcedema being found on routine examination, no other reason is found and the discs return to normal in a few months.
One is reminded of the type of benign intracranial hypertension which affects overweight women at times of hormonal imbalance, for example at the menarche or puerperium.
Secondary Effects
Secondary effects have been reported more frequently after local than systemic therapy.
Diminished tissue response to injury must be weighed carefully in deep chemical and thermal burns, where there is also the risk of secondary infection. Retardation of epithelial healing and reduction of the tensile strength of corneal wounds has been demonstrated by Aquavella et al. (1964) . This occurs only if drops are given immediately after injury.
Prolongeduse oflocal preparations inanesthetic or dry eyes (neuroparalytic keratitis or keratoconjunctivitis sicca) can be hazardous. I have recently seen 2 patients with Sjogren's syndrome develop hypopyon ulcers whilst on therapy.
The danger of local steroids in herpes simplex keratitis needs to be constantly stressed as we still see a few cases of the necrotic deep ulceration which can be saved by therapeutic grafts. With the advent of 5-iodo-2'-deoxyuridine we are able to employ steroids to depress the stromal reaction with greater safety. The position in other viral conditions is not yet clear. Complications in herpes zoster seem to be related more to secondary infection of the anesthetic cornea, generalized spread being reported very rarely on systemic therapy.
The increase of fungus infection of the eye has been ascribed in part to the prolonged use of combinations of corticosteroids and antibiotics. This potentiation of fungal keratitis can be demonstrated in rabbits (Becker 1964) . Some evidence has been presented that steroids may decrease the intraocular penetration of antibiotics. It has also been shown experimentally that there is a delay in absorption of hyphaemata and slower absorption of lens matter has been suspected clinically.
Unclassified
Discomfort may be noticed where suspension or ointment is employed and on occasions corneal erosions have been observed; this may account for the higher intraocular levels observed with cortisone suspensions than the soluble variety and the greater antiphlogistic effect (Leopold & Hogan 1962) . After subconjunctival injections of suspensions the material remains for many weeks and may ulcerate or cause granulomata especially in sarcoidosis, a type of ocular Kveim test.
Certain other effects have been noted which in the main follow local therapy and where the mechanism is still too uncertain to classify. The fascinating topic of steroid glaucoma has been dealt with by Professor Perkins. Mydriasis has also been noted in the normal eye; possible mechanisms demonstrated elsewhere in the body would be the potentiation of the adrenergic effect or a direct action on smooth muscle.
I have left the question of cataracts until last because I have little to add to what I have already published (Crews 1963) . Although the typical posterior subcapsular lens opacities have been mainly noted in patients on long-term systemic therapy they have more recently been reported following local medication (Streiff 1964 , Becker 1964 . They were originally described by Black et al. (1960) in 17 out of 44 patients with rheumatoid arthritis and later the series was expanded to 30 out of 72 including those with other diseases. The opacities could be differentiated from those due to other causes except for radiation and toxic. A relationship was found between incidence and dosage though later reports indicated considerable variation in the incidence. My own series substantially agreed with the original report from the National Institutes of Health: of 79 patients on long-term therapy for a variety of conditions 25 had typical opacities, chiefly affecting those on a moderate or high dose for more than two years. There was also a relationship between the dosage and degree of opacity. Vision remained good in half of the eyes, but in 7 it was greatly impaired. Several patients have had cataract extraction which they withstood very well. Most of the patients showed other marked steroid side-effects. The series has now increased to 39 of whom 7 (with nephrotic syndrome) are under 22 years old.
It has not proved possible to produce these opacities in animals. Probably the best indication that steroids are involved is the demonstration that in a few very early cases, after treatment has ceased, clear lens fibres are laid down outside the opacities; with local therapy, lens changes develop only in the eye receiving medication.
With regard to the management, patients on a moderate or high dose (i.e. over 10 mg preonisone or equivalent) for more than two years should be examined at intervals by an ophthalmologist. If typical opacities are found there should be a joint revaluation of the necessity for steroids: a reduction to minimal suppressing dose may ensure that opacities remain stationary. If large doses are essential then it can be advised that extraction of cataracts seems free from added risk.
With all these adverse reactions there is the difficulty of establishing whether they are caused by the therapy. Often it is suspected that the steroids act on a background of disease, impaired nutrition, or genetic predisposition, which explains the considerable delay in the recognition of these complications. There may be less risk of reactions in the presence of an active inflammatory process, because of increased local utilization of corticosteroids, and potential danger if the dosage is not reduced after the inflammation quietens, or where excess drug acts on adjacent tissues. If, for example, a powerful local preparation is instilled into the eye for a mild superficial affection (e.g. allergic conjunctivitis) a high intraocular level may lead to complications which would not have occurred had the inflammation affected deeper structures. The development of preparations with surface action but low intraocular penetration is an obvious solution.
I would re-emphasize the need for recognizing the more serious complications and for joint consultation with physicians to review steroid requirements. Further study of the mechanism of reactions may aid our basic knowledge of ocular disease and enable therapeutic products to be developed which do not have these disadvantages.
Corticosteroids have enormous value in ophthalmology. Nothing I have said detracts from their use in properly selected conditions. BIBLIOGRAPHY Aquaveila J V, Gasset A R & Dohlman C H
